(S)-4-(2-Hydroxy-3-((2-(morpholine-4-carboxamido)ethyl)amino)propoxy)phenyl 2,2-dimethylhexanoate | 1638744-45-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: (S)-4-(2-Hydroxy-3-((2-(morpholine-4-carboxamido)ethyl)amino)propoxy)phenyl 2,2-dimethylhexanoate
• 英文别名: [4-[(2S)-2-hydroxy-3-[2-(morpholine-4-carbonylamino)ethylamino]propoxy]phenyl] 2,2-dimethylhexanoate
• CAS: 1638744-45-2
• 化学式: C₂₄H₃₉N₃O₆
• 分子量: 465.6
• InChiKey: XNWAYUQNFSWYFT-IBGZPJMESA-N

物化性质

• 沸点：
  676.7±55.0 °C(Predicted)
• 密度：
  1.145±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  33
• 可旋转键数：
  14
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  109
• 氢给体数：
  3
• 氢受体数：
  7

文献信息

• Adrenergic receptor modulating compounds and methods of using the same
  申请人：The Board of Trustees of the Leland Stanford Junior University

  公开号：US11173144B2

  公开（公告）日：2021-11-16

  Adrenergic receptor modulating compounds and methods of using the same are provided. Also provided are methods of treating a subject for a disease or condition associated with an adrenergic receptor including administering a therapeutically effective amount of the subject compound. Aspects of the disclosure include a method of modulating an inflammatory pathway in a cell, such as the production of TNF-alpha in the cell. The method can include contacting a cell with β1-selective adrenergic receptor modulating compound to selectively activate a cAMP pathway over a beta-arrestin pathway in the cell. Pharmaceutical compositions and kits which include the subject compounds are provided.

  提供了肾上腺素能受体调节化合物及其使用方法。还提供了治疗与肾上腺素能受体相关的疾病或病症的方法，包括施用治疗有效量的主体化合物。本公开的各个方面包括一种调节细胞中炎症通路的方法，如细胞中 TNF-α 的产生。该方法可包括使细胞与β1选择性肾上腺素能受体调节化合物接触，以选择性地激活细胞中的cAMP通路而不是β-arrestin通路。本发明还提供了包括上述化合物的药物组合物和试剂盒。
• ADRENERGIC RECEPTOR MODULATING COMPOUNDS AND METHODS OF USING THE SAME
  申请人：The Board of Trustees of the Leland Stanford Junior University

  公开号：US20200237724A1

  公开（公告）日：2020-07-30

  Adrenergic receptor modulating compounds and methods of using the same are provided. Also provided are methods of treating a subject for a disease or condition associated with an adrenergic receptor including administering a therapeutically effective amount of the subject compound. Aspects of the disclosure include a method of modulating an inflammatory pathway in a cell, such as the production of TNF-alpha in the cell. The method can include contacting a cell with β1-selective adrenergic receptor modulating compound to selectively activate a cAMP pathway over a beta-arrestin pathway in the cell. Pharmaceutical compositions and kits which include the subject compounds are provided.
• [EN] METHOD OF IMPROVING COGNITION AND SOCIAL BEHAVIOR IN HUMANS HAVING DEFICITS THEREIN DUE TO NEUROLOGICAL DISORDERS AND COMPOUNDS AND COMPOSITIONS THEREFOR<br/>[FR] PROCEDE D'AMELIORATION DE LA COGNITION ET DU COMPORTEMENT SOCIAL CHEZ DES HUMAINES QUI EN SONT DEFICIENTS CONSECUTIFS A DE TROUBLES NEUROLOGIQUES ET COMPOSES ET COMPOSITIONS A CET EFFET
  申请人：UNIV LELAND STANFORD JUNIOR

  公开号：WO2015126915A2

  公开（公告）日：2015-08-27

  A β1-ADR agonist prodrug compound, which is hydrolysable in vivo to release a β1-ADR agonist compound, and which prodrug compound contains a group which imparts greater lipophilicity and CNS bioavailability to the prodrug compound relative to the β1-ADR agonist compound.